Regal Investment Advisors’s Alexion Pharmaceuticals ALXN Stock Holding History

Regal Investment Advisors’s Portfolio ALXN Stock Details ALXN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-18,699	Closed	-$2.27M	–	279
2017 Q1	$2.27M	Sell	18,699 -2,810	-13%	-$362K	0.59%	60
2016 Q4	$2.63M	Sell	21,509 -714	-3%	-$87.4K	0.73%	51
2016 Q3	$2.72M	Sell	22,223 -1,452	-6%	-$187K	0.77%	47
2016 Q2	$2.76M	Buy	+23,675	New	+$3.36M	0.76%	51
2015 Q4	–	Sell	-210	Closed	-$32K	–	948
2015 Q3	$32K	Buy	210 +10	+5%	+$1.82K	0.01%	483
2015 Q2	$36K	Hold	200	–	–	0.01%	475
2015 Q1	$35K	Hold	200	–	–	0.01%	482
2014 Q4	$37K	Hold	200	–	–	0.01%	440
2014 Q3	$33K	Hold	200	–	–	0.01%	477
2014 Q2	$31K	Hold	200	–	–	0.01%	474
2014 Q1	$30K	Hold	200	–	–	0.01%	438
2013 Q4	$27K	Hold	200	–	–	0.02%	396
2013 Q3	$23K	Hold	200	–	–	0.01%	449
2013 Q2	$18K	Buy	+200	New	+$19.3K	0.01%	482

Other funds holding ALXN

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Regal Investment Advisors's ALXN Position: Q2 2017 in Review

Regal Investment Advisors sold out of Alexion Pharmaceuticals (ALXN) in Q2 2017, closing a stake of 18,699 shares — an estimated $2.27M sold.

Regal Investment Advisors first reported a position in ALXN in Q2 2013 and held it in 14 quarters. The position peaked at $2.76M in Q2 2016. 559 funds tracked by Wall St. Rank hold ALXN as of Q2 2017.

Regal Investment Advisors reported no remaining Alexion Pharmaceuticals position as of Q2 2017 after selling out during the quarter.
Regal Investment Advisors sold 18,699 Alexion Pharmaceuticals shares in Q2 2017, an estimated $2.27M.
Regal Investment Advisors first reported a position in Alexion Pharmaceuticals in Q2 2013 and held it in 14 quarters.
Regal Investment Advisors's Alexion Pharmaceuticals position peaked at $2.76M in Q2 2016.
559 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q2 2017.

Based on Regal Investment Advisors's 13F filing for Q2 2017, filed 10 Aug 2017.